Figure 3. The effect of TA (two doses) on gene expression of VEGF-A and TSP-1 in three different uveal melanoma cell lines. Cells were treated with four different suspensions: Park Memorial Institute/Dulbecco’s Modified Eagle Medium (RPMI/DMEM; control; a), RPMI/DMEM with methanol (second control; b), 10 μM triamcinolone acetonide (TA) suspension (c), or 100 μM TA suspension (d). Expression levels of vascular endothelial growth factor-A (VEGF-A) and thrombospondin-1 (TSP-1) are normalized against two endogenous controls (normalized fold; mean±SD). Experiments were performed twice. VEGF-A was expressed in all cell lines at variable levels. TA treatment had no major (>1.0 fold) effect on VEGF-A expression. TSP-1 was not expressed in 92.1. Mel 285 showed a decreased TSP-1 expression (time-fold difference=1.5–2.9) after treatment with TA.